Compare ASMB & BVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | BVS |
|---|---|---|
| Founded | 2005 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 482.9M |
| IPO Year | 2010 | 2016 |
| Metric | ASMB | BVS |
|---|---|---|
| Price | $28.24 | $8.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $43.40 | $14.25 |
| AVG Volume (30 Days) | 92.6K | ★ 305.4K |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 50.00 | ★ 163.46 |
| EPS | N/A | ★ 0.33 |
| Revenue | N/A | ★ $568,087,000.00 |
| Revenue This Year | $33.33 | $7.42 |
| Revenue Next Year | N/A | $6.46 |
| P/E Ratio | ★ N/A | $26.97 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.76 | $5.81 |
| 52 Week High | $39.71 | $10.13 |
| Indicator | ASMB | BVS |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 52.95 |
| Support Level | $26.50 | $6.42 |
| Resistance Level | $30.66 | $9.01 |
| Average True Range (ATR) | 1.46 | 0.39 |
| MACD | 0.04 | -0.03 |
| Stochastic Oscillator | 36.74 | 35.19 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.